Direct mechanisms
|
Genotoxins
|
Typhoid toxin |
Salmonella enterica serovar Typhi |
In vitro and animal models |
DNAse activity; induction of symptoms characteristic of typhoid fever |
[64] |
Cytolethal distending toxin |
Proteobacteria |
Cell lines and primary cell and mouse models of chronic infections |
DNase activity; Proinflamation and carcinogenic potential |
[65,66,67] |
Colibactin |
Escherichia coli group B |
Eukaryotic cells |
DNA double-strand breaks |
[68] |
Epidemiological and animal model |
DNA double-strand breaks in vitro and in vivo; enhanced tumour growth by senescence |
[69,70] |
Alteration of host cellular cycle
|
Cytotoxin-associated gene A Vacuolating cytotoxin A |
Helicobacter pylori
|
Molecular, experimental and epidemiological |
DNA damage; Increases IL-8; produces reactive oxygen species (ROS) and nitric oxide; increases concentrations of cyclo-oxygenase 2; decreases apoptosis; and increases cell proliferation |
[66,71] |
Enterotoxin |
Bacteroides fragilis
|
In vitro and epidemiological |
DNA damage; high levels of ROS; Diarrheal disease, associated with colorectal cancer |
[62,72] |
Adhesin A |
Fusobacterium nucleatum
|
In vitro and epidemiological |
Activation of β catenin pathway |
[66,73] |
ExoS exotoxin |
Pseudomonas aeruginosa
|
In vitro, experimental and epidemiological |
Activation of pathways with final mechanism leading to DNA damage; unknown mechanisms in cancer generation |
[62,66] |
Cysteine protease-like |
Shigella flexneri
|
In vitro and epidemiological |
Potassium outflow conducting to ROS production; induce degradation of p53; DNA damage; dysentery |
[62,66] |
Avirulence protein A |
Salmonella enterica
|
In vitro and mouse model of inflammation-associated cancer |
Target β-catenin pathway; colonic tumorigenesis and tumour progression |
[66] |
Cytotoxic necrotising factor |
Escherichia coli
|
In vitro and animal models |
Activates Rho GTPase; modifies cytoskeleton; triggers G1-S transition; downregulate mismatch repair genes; the role of CNF in infections in not clear |
[71,74] |
Cycle-inhibiting factor |
In vitro |
Inhibition of mitosis |
[75] |
Secondary bile acids |
Anaerobic bacteria with 7-α dehydroxylation activity of primary bile acids |
In vitro colon cells and animal models |
Changes in physicochemical membrane properties; Apoptosis and genomic damage by ROS; Deoxycholic acid is carcinogenic at high doses and long-term treatment in animal models |
[76] |
Indirect mechanisms
|
Oxidative stress
|
Reactive oxygen species |
Peptostreptococcus anaerobius
|
In vivo, in vitro and epidemiological |
Increase of human colon tumour tissues and adenomas; these bacteria increase colon dysplasia in a mouse model of CRC by induction of ROS levels, which promotes cholesterol synthesis and cell proliferation. |
[77] |
Enterococcus faecalis
|
In vitro and in vivo models, epidemiological |
Induction of ROS, activation of macrophages; promotion of tumorigenesis |
[66,78] |
Faecal matrix |
In vitro |
Unknown reducing agent |
[79] |
Formation of H2S
|
H2S |
Sulfate-reducing bacteria |
Epidemiological and in vitro models |
Promotes instability or cumulative mutations in a predisposed genetic background |
[80] |
Inflammation
|
Wall-extracted antigen |
Streptococcus bovis
|
Epidemiological and molecular |
Activation of cyclo-oxygenase 2, interleukin 8 production, and cell proliferation |
[71] |
Disabling cellular DNA repair process
|
Listeriolysin O |
Listeria monocytogenes
|
In vitro and epidemiological |
Pore formation in intestinal host cells; Prevention of recruitment of repair complex to DNA breaks; listeriosis |
[66] |
Secreted effector protein EspF |
Escherichia coli
|
In vitro |
Down-regulation DNA mismatch repair |
[66] |
Protein metabolism
|
Phenol/indol/p-cresol/ |
Intestinal bacteria |
Colonic cells |
Increased anion superoxide production and genotoxic effects |
[81,82] |
Fecapentanes |
Bacteroides sp. |
In vitro; In vivo |
Cytotoxic and mutagenic effects via ROS production; Controversial in vivo effect |
[63,83] |
Ammonium |
Intestinal bacteria |
In vitro |
Antiproliferative effect without decrease of cell viability |
[84] |